Literature DB >> 6732227

Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

R D Blevins, C E Halstenson, N G Salem, G R Matzke.   

Abstract

The pharmacokinetics of vancomycin were studied in four patients on continuous ambulatory peritoneal dialysis. After a single intravenous infusion of 10 mg/kg of total body weight, multiple blood, urine, and dialysate samples were collected during a 72-h evaluation period. The steady-state volume of distribution was 0.73 +/- 0.07 (mean +/- standard deviation) liters/kg with a beta half-life of 90.2 +/- 24.2 h. The continuous ambulatory peritoneal dialysis clearance of vancomycin was 1.35 +/- 0.35 ml/min, and the serum clearance was 6.4 +/- 1.1 ml/min. Peritoneal dialysate concentrations of vancomycin were rapidly attained after the intravenous infusion and averaged 2.2 +/- 0.7 mg/liter throughout the 72-h observation period. A loading dose of 23 mg/kg followed by a maintenance dose of 17 mg/kg every 7 days should attain and maintain therapeutic serum and dialysate concentrations. More frequent dosing may be necessary for less susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732227      PMCID: PMC185596          DOI: 10.1128/AAC.25.5.603

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis.

Authors:  A J Morris; R T Bilinsky
Journal:  Am J Med Sci       Date:  1971-08       Impact factor: 2.378

2.  Vancomycin. A second look.

Authors:  A L Esposito; R A Gleckman
Journal:  JAMA       Date:  1977-10-17       Impact factor: 56.272

3.  Peritoneal transport of vancomycin during peritoneal dialysis.

Authors:  H E Nielsen; I Sørensen; H E Hansen
Journal:  Nephron       Date:  1979       Impact factor: 2.847

4.  Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  S Pancorbo; C Comty
Journal:  Nephron       Date:  1982       Impact factor: 2.847

5.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

Authors:  S Eykyn; I Phillips; J Evans
Journal:  Br Med J       Date:  1970-07-11

7.  Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis.

Authors:  J C Ayus; J F Eneas; T G Tong; N L Benowitz; P Y Schoenfeld; K L Hadley; C E Becker; M H Humphreys
Journal:  Clin Nephrol       Date:  1979-03       Impact factor: 0.975

8.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

9.  Study on the binding of dihydrotestosterone, testosterone and oestradiol with sex hormone binding globulin.

Authors:  F Mean; M Pellaton; G Magrini
Journal:  Clin Chim Acta       Date:  1977-10-01       Impact factor: 3.786

Review 10.  Vancomycin.

Authors:  R Fekety
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

View more
  10 in total

1.  Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis.

Authors:  G R Bailie; G Eisele; R A Venezia; D Yocum; A Hollister
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

2.  Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.

Authors:  J E Svirbely; A J Pesce; S Singh; E J O'Flaherty
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

4.  Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.

Authors:  Qingxia Liu; Huiping Huang; Baohua Xu; Dandan Li; Maobai Liu; Imam H Shaik; Xuemei Wu
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

Review 5.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

6.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.

Authors:  M C Rogge; C A Johnson; S W Zimmerman; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

9.  Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  G D Morse; D F Farolino; M A Apicella; J J Walshe
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

10.  Effect of orally administered activated charcoal on vancomycin clearance.

Authors:  R L Davis; R A Roon; J R Koup; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.